TY - JOUR T1 - Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomised, double-blind, placebo controlled phase 2 trial JF - medRxiv DO - 10.1101/2020.10.15.20213553 SP - 2020.10.15.20213553 AU - Lei Shi AU - Hai Huang AU - Xuechun Lu AU - Xiaoyan Yan AU - Xiaojing Jiang AU - Ruonan Xu AU - Siyu Wang AU - Chao Zhang AU - Xin Yuan AU - Zhe Xu AU - Lei Huang AU - Jun-Liang Fu AU - Yuanyuan Li AU - Yu Zhang AU - Weiqi Yao AU - Tianyi Liu AU - Jinwen Song AU - Liangliang Sun AU - Fan Yang AU - Xin Zhang AU - Bo Zhang AU - Ming Shi AU - Fanping Meng AU - Yanning Song AU - Yongpei Yu AU - Jiqiu Wen AU - Qi Li AU - Qing Mao AU - Markus Maeurer AU - Alimuddin Zumla AU - Chen Yao AU - Wei-Fen Xie AU - Fu-Sheng Wang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/20/2020.10.15.20213553.abstract N2 - Objective To assess the safety and efficacy of human umbilical cord-derived MSCs (UC-MSCs) for severe COVID-19 patients with lung damage.Design Multicentre, randomised, double-blind, placebo-controlled trial.Setting Two hospitals in Wuhan, China, 5 March 2020 to 28 March 2020.Participants 101 severe COVID-19 patients with lung damage aged between 18–74 years.Intervention Patients were randomly assigned at a 2:1 ratio to receive either UC-MSCs (4 × 107 cells per infusion) or placebo on days 0, 3, and 6.Main outcome measures The primary endpoints were safety and an altered proportion of whole lung lesion size from baseline to day 28, measured by chest computed tomography. Secondary outcomes were reduction of consolidation lesion sizeand lung function improvement (6-minute walk test, maximum vital capacity, diffusing capacity). Primary analysis was done in the modified intention-to-treat (mITT) population and safety analysis was done in all patients who started their assigned treatment.Results 100 patients were finally recruited to receive either UC-MSCs (n = 65) or placebo (n = 35). The patients receiving UC-MSCs exhibited a trend of numerical improvement in whole lung lesion size from baseline to day 28 compared with the placebo cases (the median difference was −13.31%, 95%CI −29.14%, 2.13%, P=0.080). UC-MSCs administration significantly reduced the proportions of consolidation lesion size from baseline to day 28 compared with the placebo (median difference: −15.45%, 95% CI −30.82%, −0.39%, P=0.043). The 6-minute walk test showed an increased distance in patients treated with UC-MSCs (difference: 27.00 m, 95% CI 0.00, 57.00, P=0.057). The incidence of adverse events was similar, and no serious adverse events were observed in the two groups.Conclusions UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19 patients with lung damage. A phase 3 trial is required to evaluate effects on reducing mortality and preventing long-term pulmonary disability.Trial registration ClinicalTrials.gov Identifier: NCT04288102Question Are human umbilical cord-derived mesenchymal stem cells (UC-MSCs) safe and effective therapeutic option for limiting lung damage in severe coronavirus disease 2019 (COVID-19)?Finding In this randomised, double-blind, placebo-controlled, phase 2 trial that included 100 COVID-19 patients with lung damage, human UC-MSCs medication showed a trend of improvement in whole lung lesion size and significantly reduced the proportions of consolidation lesions from baseline to day 28 in the treated patients compared with the placebo subjects. The 6-minute walk test showed a longer distance in UC-MSCs than placebo group but without significantly difference. UC-MSCs delivery was well tolerated, with no serious adverse events.Meaning Human UC-MSC administration for hospitalized COVID-19 with lung damage is safe. Treatment with human UC-MSC improves the resolution of lung lesions, particularly the consolidation lesions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04288102Funding StatementThis trial was supported by The National Key R&D Program of China (2020YFC0841900, 2020YFC0844000, 2020YFC08860900); The Innovation Groups of the National Natural Science Foundation of China (81721002); The National Science and Technology Major Project (2017YFA0105703). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Clinical Trial Ethics Committee of Fifth Medical Cente, Chinese PLA General Hospital (2020-013-D), the Medical Ethics Committee of Wuhan Huoshenshan Hospital(HSSLL004), the Medical Ethics Committee of Maternal and Child Hospital of Hubei Province(2020IEC001).Written informed consent was obtained from all the enrolled patients or their legal representatives if they were unable to provide consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in the manuscript are available on resonable request to Fu-Sheng Wang at fswang302@163.com. Additional information Who can access the data: researchers whose proposed use of the data has been approved Types of analysis: Such requests are at the Academic Committee's discretion and dependent on the nature of the request, the merit of the research proposed, availability of the data and the intended use of the data. Mechanisms of data availability: After approval from the Academic Committee, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed. Any additional restrictions: NA. ER -